Go Pro
→ Trump's New Dollar (From Porter & Company) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Charlie's Holdings, Inc. stock logo
CHUC
Charlie's
$0.18
+19.1%		$0.22
$0.09
▼
$0.38
$42.39M1.2947,297 shs6,159 shs
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
$10.07
-1.5%		$10.70
$9.69
▼
$22.55
$202.27M0.97194,158 shs145,052 shs
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
$2.37
+4.4%		$2.22
$1.41
▼
$3.19
$190.96MN/A947,777 shs1.23 million shs
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
$11.35
-1.0%		$12.49
$11.13
▼
$16.77
$194.15M0.93420,846 shs116,293 shs
Don't Wait for the OpenAI IPO Cover
Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Charlie's Holdings, Inc. stock logo
CHUC
Charlie's
-11.64%-11.12%-28.12%-37.04%+54.34%
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
+2.51%+0.79%-4.49%-8.09%-29.37%
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
0.00%-4.22%-2.58%+5.58%+52.35%
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
+2.50%-3.78%-14.80%-10.26%-68.93%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Charlie's Holdings, Inc. stock logo
CHUC
Charlie's
$0.18
+19.1%		$0.22
$0.09
▼
$0.38
$42.39M1.2947,297 shs6,159 shs
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
$10.07
-1.5%		$10.70
$9.69
▼
$22.55
$202.27M0.97194,158 shs145,052 shs
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
$2.37
+4.4%		$2.22
$1.41
▼
$3.19
$190.96MN/A947,777 shs1.23 million shs
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
$11.35
-1.0%		$12.49
$11.13
▼
$16.77
$194.15M0.93420,846 shs116,293 shs
Don't Wait for the OpenAI IPO Cover
Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Charlie's Holdings, Inc. stock logo
CHUC
Charlie's
-11.64%-11.12%-28.12%-37.04%+54.34%
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
+2.51%+0.79%-4.49%-8.09%-29.37%
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
0.00%-4.22%-2.58%+5.58%+52.35%
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
+2.50%-3.78%-14.80%-10.26%-68.93%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Charlie's Holdings, Inc. stock logo
CHUC
Charlie's
0.00
N/AN/AN/A
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
2.13
Hold$20.40102.58% Upside
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
3.00
Buy$12.00406.33% Upside
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
2.28
Hold$67.60495.59% Upside

Current Analyst Ratings Breakdown

Latest CHUC, KROS, RNA, and PLX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/29/2026
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeHold ➝ Strong Sell
6/19/2026
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold
6/18/2026
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
Cantor Fitzgerald logo
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOverweight$25.00
5/22/2026
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E-)
5/15/2026
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D) ➝ Sell (D-)
5/15/2026
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
Leerink Partners logo
Leerink Partners
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform
5/1/2026
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingNeutral
(Data available from 7/31/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Charlie's Holdings, Inc. stock logo
CHUC
Charlie's
$20.92M2.41$0.02 per share8.23$0.01 per share18.00
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
$244.06M0.82$4.46 per share2.26$15.51 per share0.65
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
$76.38M2.50$0.13 per share17.80$0.47 per share5.04
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
$36.68M5.29N/AN/A$10.88 per share1.04
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Charlie's Holdings, Inc. stock logo
CHUC
Charlie's
$4.50M$0.029.00N/AN/A19.33%151.74%42.26%N/A
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
$87.01M-$3.01N/AN/AN/A-256.60%-17.04%-15.84%8/5/2026 (Estimated)
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
$8.31M$0.18N/A7.65N/A-21.03%-30.89%-11.74%N/A
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
-$322.30M-$0.97N/AN/AN/A-3,650.39%-44.92%-39.57%8/13/2026 (Estimated)

Latest CHUC, KROS, RNA, and PLX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2026Q2 2026
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
-$1.16N/AN/AN/A$0.67 millionN/A
8/5/2026Q2 2026
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
-$1.25N/AN/AN/A$0.81 millionN/A
5/14/2026Q1 2026
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
-$1.0229-$1.21-$0.1871-$1.21$1.93 million$0.37 million
5/14/2026Q1 2026
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
-$1.05-$0.97+$0.08-$0.97$2.00 million$19.64 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Charlie's Holdings, Inc. stock logo
CHUC
Charlie's
N/AN/AN/AN/AN/A
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
N/AN/AN/AN/AN/A
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
N/AN/AN/AN/AN/A
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Charlie's Holdings, Inc. stock logo
CHUC
Charlie's
0.69
1.52
0.43
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
N/A
22.61
22.62
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
N/A
1.98
1.27
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
N/A
9.20
11.57

Institutional Ownership

CompanyInstitutional Ownership
Charlie's Holdings, Inc. stock logo
CHUC
Charlie's
7.80%
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
71.56%
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
16.53%
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
N/A

Insider Ownership

CompanyInsider Ownership
Charlie's Holdings, Inc. stock logo
CHUC
Charlie's
20.90%
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
12.60%
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
6.70%
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
3.83%
CompanyEmployeesShares OutstandingFree FloatOptionable
Charlie's Holdings, Inc. stock logo
CHUC
Charlie's
40280.55 million221.92 millionNot Optionable
Keros Therapeutics, Inc. stock logo
KROS
Keros Therapeutics
10019.79 million17.30 millionOptionable
Protalix BioTherapeutics, Inc. stock logo
PLX
Protalix BioTherapeutics
20080.57 million69.00 millionOptionable
Avidity Biosciences, Inc. stock logo
RNA
Avidity Biosciences
19017.11 million149.21 millionOptionable

Recent News About These Companies

Avidity Biosciences, Inc. (NASDAQ:RNA) Receives Average Recommendation of "Hold" from Analysts
July 31 at 4:43 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/avidity-biosciences-inc-nasdaqrna-receives-average-recommendation-of-hold-from-analysts-2026-07-31/
Avidity Biosciences (NASDAQ:RNA) Stock Price Crosses Below 200-Day Moving Average - Here's Why
July 22, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/avidity-biosciences-nasdaqrna-stock-price-crosses-below-200-day-moving-average-heres-why-2026-07-22/
Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
July 20, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/atrium-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-302830029.html
Atrium Therapeutics Announces FDA Clearance of Investigational New Drug Application for ATR 1072 for Treatment of PRKAG2 Syndrome
July 14, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/atrium-therapeutics-announces-fda-clearance-of-investigational-new-drug-application-for-atr-1072-for-treatment-of-prkag2-syndrome-302824844.html
Avidity Biosciences (NASDAQ:RNA) Shares Pass Below 200-Day Moving Average - Time to Sell?
July 14, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/avidity-biosciences-nasdaqrna-shares-pass-below-200-day-moving-average-time-to-sell-2026-07-14/
Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
June 23, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/atrium-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-302808194.html
Novartis Trial Wins Highlight Rhapsido And RNA FSHD Potential For Growth
June 14, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/novartis-trial-wins-highlight-rhapsido-100916277.html
Novartis RNA drug acquired in $12B Avidity deal notches a trial win
June 12, 2026  |  biopharmadive.comB
Atrium Therapeutics Reports First Quarter 2026 Financial Results
May 14, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/atrium-therapeutics-reports-first-quarter-2026-financial-results-302772898.html
Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration
April 23, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/atrium-therapeutics-earns-15-million-milestone-payment-from-bristol-myers-squibb-under-global-cardiovascular-collaboration-302751102.html
Atrium Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 20, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/atrium-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-302748022.html
Novartis Uses US Bond Issue To Expand RNA And Peptide Pipeline
March 19, 2026  |  uk.finance.yahoo.comhttps://uk.finance.yahoo.com/news/novartis-uses-us-bond-issue-170403727.html?pl2=world-indices-news_fltrd-strs
Novartis acquisition spin-off pioneers RNA therapeutics for the heart
March 19, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/novartis-acquisition-spin-off-pioneers-080000992.html
Atrium Therapeutics
March 5, 2026  |  thepharmaletter.comT
Avidity Biosciences Completes Merger and Plans Nasdaq Delisting
March 4, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/RNA-Q/pressreleases/488945/avidity-biosciences-completes-merger-and-plans-nasdaq-delisting/
Which Is a Better Investment, Exact Sciences Corporation or Avidity Biosciences, Inc. Stock?
March 2, 2026  |  aaii.comA
Atrium spins out of Avidity, aiming to target rare heart diseases with RNA
February 27, 2026  |  biopharmadive.comB
Atrium Therapeutics Launches with Approximately $270 Million to Advance Novel RNA Medicines for Rare Genetic Cardiomyopathies
February 27, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/atrium-therapeutics-launches-with-approximately-270-million-to-advance-novel-rna-medicines-for-rare-genetic-cardiomyopathies-302699662.html
Avidity Biosciences Announces Multiple Upcoming Presentations at 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
February 26, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/avidity-biosciences-announces-multiple-upcoming-presentations-at-2026-muscular-dystrophy-association-mda-clinical--scientific-conference-302698997.html
Avidity Biosciences, Inc.: Avidity Biosciences Announces Expected Record Date for Spin-Off
February 26, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-02/67773836-avidity-biosciences-inc-avidity-biosciences-announces-expected-record-date-for-spin-off-008.htm
Avidity Biosciences, Inc.: Avidity Biosciences Announces Intention to Adjourn and Reconvene Special Meeting of Stockholders
February 24, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-02/67773849-avidity-biosciences-inc-avidity-biosciences-announces-intention-to-adjourn-and-reconvene-special-meeting-of-stockholders-008.htm

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Illustration of a quantum computing chip with gold wiring and cryogenic cooling components inside a circular chamber.
2 Quantum Stocks That Could Challenge IonQ’s Leadership
By Nathan Reiff | July 15, 2026
General Mills logo displayed on an illuminated sign in a modern corporate office lobby.
General Mills Is a 5-Star Turnaround Play for Buy and Hold Investors
By Thomas Hughes | July 2, 2026
Illustration of a space station with solar panels orbiting Earth against a starry background.
3 Space Stocks That Could Outshine SpaceX After Its IPO
By Chris Markoch | July 14, 2026
A Starbucks cup with logo sits on a wooden counter inside a coffee shop with espresso equipment visible.
Starbucks Builds Sovereign AI to Cut $400 Million in Software Costs
By Jeffrey Neal Johnson | July 11, 2026
Illustration of two trees, one with gold coin leaves and one with green leaves and hanging dollar coins, symbolizing investment growth.
This Dividend ETF Choice Could Shape Your Income Strategy Through 2026
By Jessica Mitacek | July 12, 2026
Charlie's stock logo

Charlie's OTCMKTS:CHUC

$0.18 +0.03 (+19.13%)
As of 02:32 PM Eastern

Charlie's Holdings, Inc., together with its subsidiaries, formulates, markets, and distributes non-combustible nicotine-related, alternative alkaloid vapor, and hemp-derived vapor and edible products. It sells its products through distributors, specialty retailers, and third-party online resellers in the United States, the United Kingdom, Italy, Spain, New Zealand, Australia, and Canada. Charlie's Holdings, Inc. was founded in 2014 and is headquartered in Costa Mesa, California.

Keros Therapeutics stock logo

Keros Therapeutics NASDAQ:KROS

$10.07 -0.15 (-1.47%)
Closing price 04:00 PM Eastern
Extended Trading
$10.06 -0.02 (-0.15%)
As of 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-012, which is in Phase II clinical trial to treat pulmonary arterial hypertension and cardiovascular disorders; and KER-065 that is in Phase I clinical trial for the treatment of obesity and neuromuscular diseases. In addition, the company has collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize KER-050 and licensed products containing KER-050. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.

Protalix BioTherapeutics stock logo

Protalix BioTherapeutics NYSE:PLX

$2.37 +0.10 (+4.41%)
Closing price 04:00 PM Eastern
Extended Trading
$2.37 0.00 (-0.21%)
As of 06:21 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.

Avidity Biosciences stock logo

Avidity Biosciences NASDAQ:RNA

$11.35 -0.11 (-0.96%)
As of 04:00 PM Eastern

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas